Allison F Vitonis1, Linda Titus-Ernstoff, Daniel W Cramer. 1. From the Department of Obstetrics and Gynecology, Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts; and Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Abstract
OBJECTIVE: To develop a risk-factor score that may provide additional guidance to women and their physicians regarding elective bilateral salpingo-oophorectomy at the time of hysterectomy. METHODS: From a case-control study conducted from 1992 to 2008 in women residing in eastern Massachusetts or New Hampshire, we selected 1,098 women with invasive ovarian cancer (case group) and 1,363 for the control group who were older than 40 years and had neither hysterectomy nor a personal or family history of breast or ovarian cancer. Using logistic regression, we identified key risk factors and built a risk score. The score was separately assessed in 126 women in the case group and 156 in the control group with excluded prior hysterectomy to determine whether women who developed ovarian cancer could have been distinguished. RESULTS: Summing eight conditions found to be associated with ovarian cancer (Jewish ethnicity, less than 1 year of oral contraceptive use, nulliparity, no breastfeeding, no tubal ligation, painful periods or endometriosis, polycystic ovary syndrome or obesity, talc use), we created a five-level score. Assigning average risk to those with a score of 2, the odds ratios varied from 0.56 (95% confidence interval [CI] 0.42-0.74) for a score of 0-1 to 3.30 (95% CI 2.50-4.35) for a score of 5 or greater (P trend <.001). The risk score was higher for women who developed ovarian cancer after hysterectomy than those who did not (P=.01). Lifetime risks for ovarian cancer for a woman at age 40 years are changed from 1.2% with a 0-1 score to 6.6% with a score of 5 or higher. CONCLUSION: We developed a risk-assessment tool that can quantify women's risk for ovarian cancer and should be validated in other data sets.
OBJECTIVE: To develop a risk-factor score that may provide additional guidance to women and their physicians regarding elective bilateral salpingo-oophorectomy at the time of hysterectomy. METHODS: From a case-control study conducted from 1992 to 2008 in women residing in eastern Massachusetts or New Hampshire, we selected 1,098 women with invasive ovarian cancer (case group) and 1,363 for the control group who were older than 40 years and had neither hysterectomy nor a personal or family history of breast or ovarian cancer. Using logistic regression, we identified key risk factors and built a risk score. The score was separately assessed in 126 women in the case group and 156 in the control group with excluded prior hysterectomy to determine whether women who developed ovarian cancer could have been distinguished. RESULTS: Summing eight conditions found to be associated with ovarian cancer (Jewish ethnicity, less than 1 year of oral contraceptive use, nulliparity, no breastfeeding, no tubal ligation, painful periods or endometriosis, polycystic ovary syndrome or obesity, talc use), we created a five-level score. Assigning average risk to those with a score of 2, the odds ratios varied from 0.56 (95% confidence interval [CI] 0.42-0.74) for a score of 0-1 to 3.30 (95% CI 2.50-4.35) for a score of 5 or greater (P trend <.001). The risk score was higher for women who developed ovarian cancer after hysterectomy than those who did not (P=.01). Lifetime risks for ovarian cancer for a woman at age 40 years are changed from 1.2% with a 0-1 score to 6.6% with a score of 5 or higher. CONCLUSION: We developed a risk-assessment tool that can quantify women's risk for ovarian cancer and should be validated in other data sets.
Authors: R B Ness; J A Grisso; C Cottreau; J Klapper; R Vergona; J E Wheeler; M Morgan; J J Schlesselman Journal: Epidemiology Date: 2000-03 Impact factor: 4.822
Authors: Margaret A Gates; Shelley S Tworoger; Kathryn L Terry; Linda Titus-Ernstoff; Bernard Rosner; Immaculata De Vivo; Daniel W Cramer; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-09 Impact factor: 4.254
Authors: Kim N Danforth; Shelley S Tworoger; Jonathan L Hecht; Bernard A Rosner; Graham A Colditz; Susan E Hankinson Journal: Cancer Causes Control Date: 2007-04-21 Impact factor: 2.506
Authors: William H Parker; Michael S Broder; Eunice Chang; Diane Feskanich; Cindy Farquhar; Zhimae Liu; Donna Shoupe; Jonathan S Berek; Susan Hankinson; JoAnn E Manson Journal: Obstet Gynecol Date: 2009-05 Impact factor: 7.661
Authors: Shelley S Tworoger; Kathleen M Fairfield; Graham A Colditz; Bernard A Rosner; Susan E Hankinson Journal: Am J Epidemiol Date: 2007-07-26 Impact factor: 4.897
Authors: Kevin M Elias; S Intidhar Labidi-Galy; Allison F Vitonis; Jason L Hornick; Leona A Doyle; Michelle S Hirsch; Daniel W Cramer; Ronny Drapkin Journal: Gynecol Oncol Date: 2013-12-14 Impact factor: 5.482
Authors: Benjamin A Katchman; Diego Chowell; Garrick Wallstrom; Allison F Vitonis; Joshua LaBaer; Daniel W Cramer; Karen S Anderson Journal: Gynecol Oncol Date: 2017-04-18 Impact factor: 5.482
Authors: Babatunde O Akinwunmi; Ana Babic; Allison F Vitonis; Daniel W Cramer; Linda Titus; Shelley S Tworoger; Kathryn L Terry Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-09-20 Impact factor: 4.254
Authors: Holly R Harris; Immaculata De Vivo; Linda J Titus; Allison F Vitonis; Jason Y Y Wong; Daniel W Cramer; Kathryn L Terry Journal: Int J Mol Epidemiol Genet Date: 2012-08-31
Authors: Holly R Harris; Megan S Rice; Amy L Shafrir; Elizabeth M Poole; Mamta Gupta; Jonathan L Hecht; Kathryn L Terry; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-13 Impact factor: 4.254
Authors: Naoko Sasamoto; Ana Babic; Bernard A Rosner; Renée T Fortner; Allison F Vitonis; Hidemi Yamamoto; Raina N Fichorova; Anne Tjønneland; Louise Hansen; Kim Overvad; Marina Kvaskoff; Agnès Fournier; Francesca Romana Mancini; Heiner Boeing; Antonia Trichopoulou; Eleni Peppa; Anna Karakatsani; Domenico Palli; Valeria Pala; Amalia Mattiello; Rosario Tumino; Chiara C Grasso; N Charlotte Onland-Moret; Elisabete Weiderpass; J Ramón Quirós; Leila Lujan-Barroso; Miguel Rodríguez-Barranco; Sandra Colorado-Yohar; Aurelio Barricarte; Miren Dorronsoro; Annika Idahl; Eva Lundin; Hanna Sartor; Kay-Tee Khaw; Timothy J Key; David Muller; Elio Riboli; Marc J Gunter; Laure Dossus; Rudolf Kaaks; Daniel W Cramer; Shelley S Tworoger; Kathryn L Terry Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-04-04 Impact factor: 4.254
Authors: Merlise A Clyde; Rachel Palmieri Weber; Edwin S Iversen; Elizabeth M Poole; Jennifer A Doherty; Marc T Goodman; Roberta B Ness; Harvey A Risch; Mary Anne Rossing; Kathryn L Terry; Nicolas Wentzensen; Alice S Whittemore; Hoda Anton-Culver; Elisa V Bandera; Andrew Berchuck; Michael E Carney; Daniel W Cramer; Julie M Cunningham; Kara L Cushing-Haugen; Robert P Edwards; Brooke L Fridley; Ellen L Goode; Galina Lurie; Valerie McGuire; Francesmary Modugno; Kirsten B Moysich; Sara H Olson; Celeste Leigh Pearce; Malcolm C Pike; Joseph H Rothstein; Thomas A Sellers; Weiva Sieh; Daniel Stram; Pamela J Thompson; Robert A Vierkant; Kristine G Wicklund; Anna H Wu; Argyrios Ziogas; Shelley S Tworoger; Joellen M Schildkraut Journal: Am J Epidemiol Date: 2016-10-03 Impact factor: 4.897